RESUMO
OBJECTIVES: To compare the mortality of monochorionic-monoamniotic (MCMA) and monochorionic-biamniotic (MCBA) twin pregnancies, from 14weeks of gestation to 28th day of life, before and after exclusion of major congenital malformations. METHODS: We conducted a retrospective cohort study in two level 3 maternity units of the Hospices civils de Lyon (France) including all patients with a monochorionic twin pregnancy between January 2013 and December 2020. We excluded TRAP sequences and conjoined twins. RESULTS: A total of 38 MCMA and 658 MCBA pregnancies were included. We showed an increase in overall mortality in the MCMA group compared to the MCBA group (31.6% versus 16.4%, P=0.03) even after exclusion of major congenital malformations (20.3% versus 9.5%, P=0.01). The main cause of mortality found in the MCMA group was the occurrence of unexpected IUGR. CONCLUSIONS: MCMA pregnancies have a higher foetal and neonatal mortality rate than MCBA pregnancies even after exclusion of congenital malformations related to the occurrence of unexpected MFIU.
Assuntos
Gravidez de Gêmeos , Gêmeos Monozigóticos , Feminino , Humanos , Recém-Nascido , Gravidez , Mortalidade Infantil , Cuidado Pré-Natal , Estudos RetrospectivosRESUMO
OBJECTIVES: Evaluate the prevalence of uterine synechia after total uterine ligation (TUL) in comparison to TUL associated with compression-penetrating-sutures (CPS) in the conservative surgical management of severe postpartum hemorrhage (PPH). METHODS: Prospective observational study of pregnant women that underwent conservative surgical management for PPH in a single French tertiary referral center. We compared the risk of uterine synechia with TUL, in comparison to performing TUL in addition to CPS. The synechia rate was calculated after uterine cavity assessment by 3D hysterosonography. Hysterectomies, women with placenta accreta spectrum and patients that received additional embolization treatment were excluded. RESULTS: Over 6 years, 36 pregnant women underwent surgical treatment for PPH in 21,944 deliveries (1.64 per 1000). The median blood loss was 2700 [1570-3000] milliliters. Twenty-eight (77.7%) women underwent TUL, 8/36 (22.2%) underwent TUL in addition to CPS. Thirty-four (94,4%) cavity assessments were performed 2-to-6 months after delivery, since one woman of each group was lost to follow-up. When TUL was performed in addition to CPS, the prevalence of synechia was 42.9% (n = 3/7), versus 3.7% (n = 1/27) in TUL (p = 0.021; RR = 16.88, 95%CI [1.1-1051]). Synechia was absent in 30/34 (88.2%) women. CONCLUSION: The prevalence of synechia was very low after TUL unlike CPS. Further studies should evaluate TUL in the conservative surgical management of PPH, to confirm the lower prevalence of synechiae in TUL and evaluate its impact on fertility.
Assuntos
Placenta Acreta , Hemorragia Pós-Parto , Feminino , Humanos , Gravidez , Masculino , Hemorragia Pós-Parto/epidemiologia , Hemorragia Pós-Parto/etiologia , Hemorragia Pós-Parto/cirurgia , Técnicas de Sutura , Suturas , Placenta Acreta/cirurgia , Aderências Teciduais/cirurgia , Período Pós-PartoRESUMO
OBJECTIVE: To assess the benefits and safety of early human fibrinogen concentrate in postpartum haemorrhage (PPH) management. DESIGN: Multicentre, double-blind, randomised placebo-controlled trial. SETTING: 30 French hospitals. POPULATION: Patients with persistent PPH after vaginal delivery requiring a switch from oxytocin to prostaglandins. METHODS: Within 30 minutes after introduction of prostaglandins, patients received either 3 g fibrinogen concentrate or placebo. MAIN OUTCOME MEASURES: Failure as composite primary efficacy endpoint: at least 4 g/dl of haemoglobin decrease and/or transfusion of at least two units of packed red blood cells within 48 hours following investigational medicinal product administration. Secondary endpoints: PPH evolution, need for haemostatic procedures and maternal morbidity-mortality within 6 ± 2 weeks after delivery. RESULTS: 437 patients were included: 224 received FC and 213 placebo. At inclusion, blood loss (877 ± 346 ml) and plasma fibrinogen (4.1 ± 0.9 g/l) were similar in both groups (mean ± SD). Failure rates were 40.0% and 42.4% in the fibrinogen and placebo groups, respectively (odds ratio [OR] = 0.99) after adjustment for centre and baseline plasma fibrinogen; (95% CI 0.66-1.47; P = 0.96). No significant differences in secondary efficacy outcomes were observed. The mean plasma FG was unchanged in the Fibrinogen group and decreased by 0.56 g/l in the placebo group. No thromboembolic or other relevant adverse effects were reported in the Fibrinogen group versus two in the placebo group. CONCLUSIONS: As previous placebo-controlled studies findings, early and systematic administration of 3 g fibrinogen concentrate did not reduce blood loss, transfusion needs or postpartum anaemia, but did prevent plasma fibrinogen decrease without any subsequent thromboembolic events. TWEETABLE ABSTRACT: Early systematic blind 3 g fibrinogen infusion in PPH did not reduce anaemia or transfusion rate, reduced hypofibrinogenaemia and was safe.
Assuntos
Parto Obstétrico/efeitos adversos , Fibrinogênio/administração & dosagem , Hemostáticos/administração & dosagem , Hemorragia Pós-Parto/tratamento farmacológico , Adulto , Transfusão de Sangue/estatística & dados numéricos , Parto Obstétrico/métodos , Método Duplo-Cego , Feminino , Humanos , Ocitócicos/administração & dosagem , Ocitocina/administração & dosagem , Gravidez , Prostaglandinas/administração & dosagem , Prevenção Secundária , Resultado do Tratamento , VaginaRESUMO
INTRODUCTION: Spontaneous adrenal hemorrhages (AH) are a rare condition with no consensus about their management. METHODS: Patients were identified using the Medicalization of the Information System Program database, imaging software and a call for observations to internists, intensivists and obsetricians working at our institution. Adult patients whose medical records were complete and whose diagnosis was confirmed by medical imaging were included. RESULTS: From 2000 to 2007, 20 patients were identified, including 15 were women. The clinical onset of AH was non-specific. In five cases, AH occurred during pregnancy; four of them were unilateral and right sided. The etiology of the other fifteen (bilateral adrenal hemorrhage in 11) were as follows: antiphospholipid syndrome (n=8), heparin-induced thrombocytopenia (n=4), essential thrombocythemia (n=3), spontaneous AH due to oral anticoagulants (n=1), complication of a surgical act (n=3), and sepsis (n=3). In seven cases, two causes were concomitant. The diagnosis of AH was often confirmed by abdominal CT. An anticoagulant treatment was initiated in 16 cases. Ten of the eleven patients presenting with bilateral adrenal hematomas were treated using a long-term substitute opotherapy. One patient died because of a catastrophic antiphospholipid syndrome. CONCLUSION: The clinical onset of HS is heterogeneous and non-specific. The confirmatory diagnosis is often based on abdominal CT. The search for an underlying acquired thrombophilia is essential and we found in this study etiological data comparable to the main series in the literature. Adrenal insufficiency is most of the time definitive in cases of bilateral involvement.
Assuntos
Doenças das Glândulas Suprarrenais , Síndrome Antifosfolipídica , Doenças das Glândulas Suprarrenais/diagnóstico , Doenças das Glândulas Suprarrenais/epidemiologia , Doenças das Glândulas Suprarrenais/terapia , Adulto , Anticoagulantes/uso terapêutico , Síndrome Antifosfolipídica/complicações , Síndrome Antifosfolipídica/diagnóstico , Síndrome Antifosfolipídica/epidemiologia , Feminino , Hematoma/diagnóstico , Hematoma/epidemiologia , Hematoma/etiologia , Hemorragia , Humanos , Gravidez , Estudos RetrospectivosRESUMO
OBJECTIVE: To describe and compare the characteristics of women with placenta accreta spectrum (PAS) and their pregnancy outcomes according to the presence of placenta praevia and a prior caesarean section. DESIGN: Prospective population-based study. SETTING: All 176 maternity hospitals of eight French regions. POPULATION: Two hundred and forty-nine women with PAS, from a source population of 520 114 deliveries. METHODS: Women with PAS were classified into two risk-profile groups, with or without the high-risk combination of placenta praevia (or an anterior low-lying placenta) and at least one prior caesarean. These two groups were described and compared. MAIN OUTCOME MEASURES: Population-based incidence of PAS, characteristics of women, pregnancies, deliveries and pregnancy outcomes. RESULTS: The PAS population-based incidence was 4.8/10 000 (95% CI 4.2-5.4/10 000). After exclusion of women lost to follow up from the analysis, the group with placenta praevia and a prior caesarean included 115 (48%) women and the group without this combination included 127 (52%). In the group with both factors, PAS was more often suspected antenatally (77% versus 17%; P < 0.001) and more often percreta (38% versus 5%; P < 0.001). This group also had more hysterectomies (53% versus 21%, P < 0.001) and higher rates of blood product transfusions, maternal complications, preterm births and neonatal intensive care unit admissions. Sensitivity analysis showed similar results after exclusion of women who delivered vaginally. CONCLUSION: More than half the cases of PAS occurred in women without the combination of placenta praevia and a prior caesarean delivery, and these women had better maternal and neonatal outcomes. We cannot completely rule out that some of the women who delivered vaginally had placental retention rather than PAS; however, we found similar results among women who delivered by caesarean. TWEETABLE ABSTRACT: Half the women with PAS do not have both placenta praevia and a prior caesarean delivery, and they have better maternal outcomes.
Assuntos
Cesárea , Placenta Acreta/epidemiologia , Placenta Prévia , Adulto , Feminino , França/epidemiologia , Humanos , Placenta Acreta/etiologia , Gravidez , Resultado da Gravidez , Estudos ProspectivosRESUMO
OBJECTIVES: Increased nuchal translucency (NT) thickness is an antenatal marker of aneuploidy or malformation that can lead to termination of pregnancy. This study assessed the long-term neurodevelopmental prognosis of infants who had isolated increased NT in utero. METHODS: This was a prospective cohort study of infants with a NT thickness > 95th percentile in the first trimester, but with a normal karyotype and no major anomalies, and controls with normal NT matched for birth weight, Apgar score, place of birth, parity and gestational age at birth. At 2 years of corrected age, all infants underwent the psychometric Brunet-Lézine test to evaluate their developmental quotient (DQ), overall (global) and specifically for the areas of posture, language, coordination and sociability. RESULTS: A total of 203 chromosomally normal infants were included in the increased-NT group and 208 in the control group. The mean global DQ was significantly lower in the increased-NT group than in the control group (108.6 ± 9.7 vs 112.8 ± 8.3; P < 0.0001), but it was within the normal range expected for that age in both groups. Similarly, the mean DQs for coordination, sociability and language, but not for posture, were significantly lower in infants with increased NT than in controls. Only one case with increased NT had a DQ < 70 (defined as severe neurodevelopmental impairment), compared with none in the control group. The difference between the two groups remained significant for a NT threshold ≥ 99th percentile and when the data were adjusted for NT thickness, the infant's sex and the mother's educational level. In the increased-NT group, NT thickness was < 3.5 mm in over half (56%) of the infants, between 3.5 mm and 5 mm in 33% and > 5 mm in 11%, with a mean global DQ of 108.4, 110.1 and 109.7, respectively. CONCLUSIONS: Infants who had isolated increased fetal NT in the first trimester had a significantly lower, but normal, DQ at a corrected age of 2 years, when compared with controls. The findings were independent of the infant's sex, fetal NT thickness and the mother's educational level. © 2020 Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Assuntos
Feto/patologia , Transtornos do Neurodesenvolvimento/epidemiologia , Medição da Translucência Nucal/estatística & dados numéricos , Adulto , Estudos de Casos e Controles , Pré-Escolar , Feminino , Feto/diagnóstico por imagem , Humanos , Lactente , Recém-Nascido , Cariótipo , Masculino , Testes de Estado Mental e Demência , Transtornos do Neurodesenvolvimento/diagnóstico , Transtornos do Neurodesenvolvimento/etiologia , Gravidez , Primeiro Trimestre da Gravidez , Prevalência , Estudos ProspectivosRESUMO
OBJECTIVES: The coronavirus SARS-CoV-2 identified late 2019 in China had spread across all continents. In the majority of cases, patients have mild symptoms (fever, cough, myalgia, headache, some digestive disorders) or are asymptomatic, however it can cause serious lung diseases and lead to death. On September 2020, over 28 million people have been infected with over 920,000 deaths. METHODS: In view of the evolution of the epidemic the French National College of Obstetricians and Gynecologists has decided to update the recommendations previously issued. To do this, the same group of experts was called upon to carry out a review of the literature and take into account the opinions of the General Directorate of Health (DGS), the "Haute Autorité de Santé" (HAS) and the "Haut Conseil de santé Publique" (HCSP). RESULTS: The data on consequences during pregnancy have accumulated. The symptoms in pregnant women appear to be similar to those of the general population, but an increased risk of respiratory distress exists in pregnant women especially in the third trimester. A case of intrauterine maternal-fetal transmission has been clearly identified. Induced prematurity and cases of respiratory distress in newborns of infected mothers have been described. CONCLUSION: In light of the new data, we propose updated recommendations. These proposals may continue to evolve in view of the pandemic and of advances in studies in pregnant women.
Assuntos
Betacoronavirus , Infecções por Coronavirus/complicações , Infecções por Coronavirus/epidemiologia , Pneumonia Viral/complicações , Pneumonia Viral/epidemiologia , Complicações Infecciosas na Gravidez/epidemiologia , Avaliação de Sintomas , COVID-19 , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/mortalidade , Feminino , França/epidemiologia , Humanos , Masculino , Pandemias , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/mortalidade , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Terceiro Trimestre da Gravidez , SARS-CoV-2RESUMO
A new coronavirus (SARS-CoV-2) highlighted at the end of 2019 in China is spreading across all continents. Most often at the origin of a mild infectious syndrome, associating mild symptoms (fever, cough, myalgia, headache and possible digestive disorders) to different degrees, SARS-Covid-2 can cause serious pulmonary pathologies and sometimes death. Data on the consequences during pregnancy are limited. The first Chinese data published seem to show that the symptoms in pregnant women are the same as those of the general population. There are no cases of intrauterine maternal-fetal transmission, but cases of newborns infected early suggest that there could be vertical perpartum or neonatal transmission. Induced prematurity and cases of respiratory distress in newborns of infected mothers have been described. Pregnancy is known as a period at higher risk for the consequences of respiratory infections, as for influenza, so it seems important to screen for Covid-19 in the presence of symptoms and to monitor closely pregnant women. In this context of the SARS-Covid-2 epidemic, the societies of gynecology-obstetrics, infectious diseases and neonatalogy have proposed a French protocol for the management of possible and proven cases of SARS-Covid-2 in pregnant women. These proposals may evolve on a daily basis with the advancement of the epidemic and knowledge in pregnant women. Subsequently, an in-depth analysis of cases in pregnant women will be necessary in order to improve knowledge on the subject.
Assuntos
Betacoronavirus , Infecções por Coronavirus/terapia , Transmissão Vertical de Doenças Infecciosas , Obstetrícia/normas , Pneumonia Viral/terapia , Complicações Infecciosas na Gravidez/diagnóstico , COVID-19 , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/transmissão , Feminino , Guias como Assunto , Humanos , Recém-Nascido , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Pandemias , Pneumonia Viral/diagnóstico , Pneumonia Viral/transmissão , Gravidez , Complicações Infecciosas na Gravidez/prevenção & controle , SARS-CoV-2 , Sociedades MédicasRESUMO
OBJECTIVES: To evaluate an in situ training program on caradiotocography interpretation during labor in the Auvergne-Rhône-Alpes region (France). METHODS: Fifteen hospital maternity unit took part to an "outreach visit" training on fetal cardiotocography interpretation between November 2011 and 2015. Professionals were asked to answer to a 10 questions test based on the French classification of fetal heart rate, at inclusion (Test 0: T0), immediately after (Test 1: T1), and long time after the training (Test 2: T2). The mean score for each maternity (T0, T1, T2) was compared individually. Subgroup analysis considered the level of perinatal care of each maternity (level 1 or 2) and the type of practice (public or private). RESULTS: The study included 332 healthcare professionals belonging to 8 level 1 (53.5%) and 7 level 2 (47.7%) maternity units. The T0 mean score was 4.79 (IC 95% [4.54; 5.02]) instead of 6.71(IC 95% [6.49; 6.93]) at T1 (P<0.05). Seventeen professionals (22.9%) answered T2 with a mean time of 35.2 months (Median value: 40 months) and a mean score of 5.32. The mean score was significantly higher at T2 than at T0 (5.32-IC 95%[4.94-5.70] (P<0.001) but lower than the score at T1 (P<0.05). CONCLUSION: An "outreach visit" training on fetal cardiotocography interpretation improves theknowledge of healthcare professionals at short and long term.
Assuntos
Cardiotocografia/métodos , Pessoal de Saúde/educação , Frequência Cardíaca Fetal , Trabalho de Parto , Feminino , França , Humanos , Assistência Perinatal/métodos , GravidezRESUMO
INTRODUCTION: To assess the obstetric outcome of pregnancies occurring after a complete uterine rupture. METHODS: Descriptive study of a series of 11 pregnancies after complete uterine rupture. RESULTS: This study includes 10 women with 11 pregnancies. There were no recurrences of complete uterine rupture. All women had cesarean deliveries between 32 and 37 weeks' gestation. There were no cases of either severe hemorrhage or placenta accreta and no maternal or neonatal deaths. All women had close clinical and ultrasound monitoring and were hospitalized during the third trimester. CONCLUSION: Women with a history of complete uterine rupture can have a subsequent pregnancy with a thoroughly favorable outcome with appropriate care conditions, including prophylactic caesarean section.
Assuntos
Cesárea , Resultado da Gravidez , Ruptura Uterina , Adulto , Feminino , Humanos , Gravidez , Recidiva , Estudos RetrospectivosRESUMO
OBJECTIVE: To evaluate the ultrasound measurement of the observed-to-expected (o/e) lung-to-head ratio (LHR) and the Quantitative Lung Index (QLI) for the prediction of pulmonary hypoplasia in the pre-viable preterm premature ruptures of membranes (PPROM) before 24 weeks gestational age (GA). METHODS: Thirty-four patients with a PPROM before 24 weeks GA and who delivered a live birth between October 2008 and October 2015 at Croix-Rousse's hospital were included. The measurements of both the LHR (right, left and total) and the QLI (right, left) were retrospectively performed by ultrasounds during the latency period. The observed LHR was divided by the expected LHR, which was obtained from recent literature data. The primary outcome was the onset of a lethal pulmonary hypoplasia. Receiver operating characteristics (ROC) curves assessed the predictive value of these ultrasound measurements for pulmonary hypoplasia. RESULTS: The areas under the ROC curves (AUCs) for the right o/eLHR, the right QLI and the total o/e LHR measured by manually drawing the pulmonary area on the last ultrasound before the delivery, were respectively 0.87 [95% CI: 0.75-1], 0.83 [95% CI: 0.69-0.98] and 0.78 [95% CI: 0.51-1]. Only the total o/e LHR measurements remained associated with lethal pulmonary hypoplasia after adjusting for prematurity and persistent oligohydramnios. CONCLUSION: The right and total o/eLHR and the right QLI measurements might be helpful in predicting pulmonary hypoplasia in pre-viable PPROM.
Assuntos
Anormalidades Múltiplas/diagnóstico por imagem , Ruptura Prematura de Membranas Fetais , Doenças do Prematuro/diagnóstico por imagem , Pneumopatias/diagnóstico por imagem , Pulmão/anormalidades , Pulmão/diagnóstico por imagem , Ultrassonografia , Anormalidades Múltiplas/mortalidade , Feminino , Idade Gestacional , Cabeça , Humanos , Recém-Nascido , Doenças do Prematuro/mortalidade , Pneumopatias/mortalidade , Oligo-Hidrâmnio , Gravidez , Resultado da Gravidez , Curva ROC , Estudos Retrospectivos , Ultrassonografia Pré-NatalRESUMO
OBJECTIVES: This study aims to describe how microarray comparative genomic hybridization (aCGH) has shifted to become a prenatal diagnosis tool at the Lyon university-hospital. MATERIALS AND METHODS: This retrospective study included all patients who were referred in the 3 pluridisciplinary centers for prenatal diagnosis of the Lyon university-hospital and who received a prenatal aCGH between June 2013 and June 2015. aCGH was systematically performed in parallel with a karyotype, using the PréCytoNEM array design. RESULTS: A total of 260 microarrays were performed for the following indications: 249 abnormal ultrasounds (95.8%), 7 characterizations of chromosomal rearrangements (2.7%), and 4 twins with no abnormal ultrasounds (1.5%). With a resolution of 1 mega base, we found 235 normal results (90.4%), 23 abnormal results (8.8%) and 2 non-returns (0.8%). For the chromosomal rearrangements visible on the karyotype, aCGH identified all of the 12 unbalanced rearrangements and did not identify the 2 balanced rearrangements. Among the fetuses with normal karyotypes, 11 showed abnormal microarray results, corresponding to unbalanced cryptic chromosomal rearrangements (4.2%). CONCLUSION: Transferring aCGH to a prenatal diagnosis at the Lyon university-hospital has increased the detection rate of chromosomal abnormalities by 4.2% compared to the single karyotype.
Assuntos
Aberrações Cromossômicas , Transtornos Cromossômicos/diagnóstico , Hibridização Genômica Comparativa , Diagnóstico Pré-Natal , Adolescente , Adulto , Feminino , França , Hospitais Universitários , Humanos , Gravidez , Estudos Retrospectivos , Adulto JovemRESUMO
Essentials Pregnancy is a risk factor for thrombosis. Management of thrombosis risk in pregnancy remains a challenge. Prophylaxis needs to be personalized. Our score may be a helpful tool for the management of pregnancies at high risk of thrombosis. SUMMARY: Background Patients with thrombophilia and/or a history of venous thromboembolism (VTE) are at risk of thrombosis during pregnancy. A risk score for pregnancies with an increased risk of VTE was previously described by our group (Lyon VTE score). Objectives The aim of this prospective study was to assess the efficacy and safety of our score-based prophylaxis strategy in 542 pregnancies managed between 2005 and 2015 in Lyon University Hospitals. Patients/Methods Of 445 patients included in the study, 36 had several pregnancies during the study period. Among these 445 patients, 279 had a personal history of VTE (62.7%), 299 patients (67.2%) had a thrombophilia marker, and 131 (29.4%) thrombophilic women had a personal history of VTE. During pregnancy, patients were assigned to one of three prophylaxis strategies according to the risk scoring system. Results In the antepartum period, low molecular weight heparin (LMWH) prophylaxis was prescribed to 64.5% of patients at high risk of VTE. Among them, 34.4% were treated in the third trimester only, and 30.1% were treated throughout pregnancy. During the postpartum period, all patients received LMWH for at least 6 weeks. Two antepartum-related VTEs (0.37%; one with a score of < 3 and the other with a score of > 6) and four postpartum-related VTEs (0.73%; three with scores of 3-5 and one with a score of > 6) occurred. No case of pulmonary embolism was observed during the study period. The rate of bleeding was 0.37%. No serious bleeding requiring transfusions or surgery occurred during the study period. Conclusion The use of a risk score may provide a rational decision process to implement safe and effective antepartum thromboprophylaxis in pregnant women at high risk of VTE.
Assuntos
Anticoagulantes/administração & dosagem , Coagulação Sanguínea/efeitos dos fármacos , Técnicas de Apoio para a Decisão , Heparina de Baixo Peso Molecular/administração & dosagem , Complicações Hematológicas na Gravidez/prevenção & controle , Tromboembolia Venosa/prevenção & controle , Adulto , Anticoagulantes/efeitos adversos , Tomada de Decisão Clínica , Feminino , França , Hemorragia/induzido quimicamente , Heparina de Baixo Peso Molecular/efeitos adversos , Hospitais Universitários , Humanos , Valor Preditivo dos Testes , Gravidez , Complicações Hematológicas na Gravidez/sangue , Complicações Hematológicas na Gravidez/diagnóstico , Complicações Hematológicas na Gravidez/etiologia , Estudos Prospectivos , Medição de Risco , Fatores de Risco , Resultado do Tratamento , Tromboembolia Venosa/sangue , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/etiologiaRESUMO
OBJECTIVE: To demonstrate the feasibility and efficacy of high-intensity focused ultrasound (HIFU) for the non-invasive creation of placental lesions in a simian model. METHODS: Eight pregnant monkeys were exposed to HIFU treatment after anesthesia, using a toroidal HIFU 2.5-MHz transducer with an integrated ultrasound imaging probe. Lesions on the placental tissue were created non-invasively by placing the HIFU probe on the skin surface. Fetal and maternal parameters, such as maternal heart rate, fetal heart rate and subcutaneous and intra-amniotic fluid temperature, were recorded during HIFU exposure. Cesarean section was performed immediately after the procedure to extract the placenta and examine the fetus and the maternal abdominal cavity. Placental HIFU lesions were assessed by ultrasound, gross pathology and histology. RESULTS: The mean gestational age of the monkeys was 72 ± 4 days. In total, 13 HIFU procedures were performed. The acoustic power and exposure time were increased progressively. This gradual increase in total energy delivered was used to determine a set of parameters to create reproducible lesions in the placenta without complications. Five placental lesions were observed with average diameters of 6.4 ± 0.5 mm and 7.8 ± 0.7 mm and an average depth of 3.8 ± 1.5 mm. Ultrasound examination of the placentae revealed hyperechoic regions that correlated well with macroscopic analysis of the HIFU lesions. Necrosis of placental tissue exposed to HIFU was confirmed with macroscopic and microscopic analysis. There was no significant variation in maternal and fetal parameters during HIFU exposure. CONCLUSIONS: This study demonstrates the feasibility of HIFU applied non-invasively to the placental unit in an in-vivo pregnant monkey model. The technique is safe in the immediate short term and is potentially translatable to human pregnancy. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.
Assuntos
Tratamento por Ondas de Choque Extracorpóreas/métodos , Doenças Placentárias/terapia , Ultrassonografia Pré-Natal/métodos , Animais , Estudos de Viabilidade , Feminino , Idade Gestacional , Haplorrinos , Modelos Animais , Doenças Placentárias/etiologia , Gravidez , Resultado do TratamentoRESUMO
BACKGROUND: Beneficial effects of tranexamic acid (TA) have been established in surgery and trauma. In ongoing postpartum haemorrhage (PPH), a moderate reduction of blood loss was observed in a previously published randomized controlled trial. Analysis of haemostasis parameters obtained from samples collected as part of this study are presented. METHODS: Women with PPH >800 ml after vaginal delivery were assigned to receive either TA (4 g over 1 h, then 1 g per h over six h) (TA) or not (H). A non-haemorrhagic group (NH), <800 ml blood loss, was included as postpartum reference. At four time-points (enrolment, +30 min, +2 h, +6 h), haemostasis was assessed. Haemostasis assays were performed blinded to group allocation. Data were expressed as median [interquartiles] and compared with non-parametric tests. RESULTS: In H compared with NH group, D-dimers increase (3730 ng ml(-1) [2468-8493] vs 2649 [2667-4375]; P=0.0001) and fibrinogen and factor II decrease were observed at enrolment and became maximal 2 h later. When comparing TA to H patients, the increase in Plasmin-Antiplasmin-complexes at +30 min (486 ng ml(-1) [340-1116] vs 674 [548-1640]; P=0.03) and D-dimers at +2 h (3888 ng ml(-1) [2688-6172] vs 7495 [4400-15772]; P=0.0001) was blunted. TA had no effect on fibrinogen decrease. CONCLUSIONS: This study provides biological evidence of an early increase in D-dimers and plasmin-antiplasmin complexes associated with active post-partum haemorrhage and its attenuation by the early use of a clinically effective high dose of TA, opening the perspective of dose ranging studies to determinate the optimal dose and timing in this setting. CLINICAL TRIAL REGISTRATION: ISRCTN09968140.
Assuntos
Antifibrinolíticos/uso terapêutico , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Hemostasia/efeitos dos fármacos , Hemorragia Pós-Parto/prevenção & controle , Ácido Tranexâmico/uso terapêutico , Antifibrinolíticos/farmacologia , Fatores de Coagulação Sanguínea/metabolismo , Coleta de Amostras Sanguíneas/métodos , Feminino , Humanos , Hemorragia Pós-Parto/sangue , Gravidez , Método Simples-Cego , Ácido Tranexâmico/farmacologiaRESUMO
A Zika virus epidemic is currently ongoing in the Americas. This virus is linked to congenital infections with potential severe neurodevelopmental dysfunction. However, incidence of fetal infection and whether this virus is responsible of other fetal complications are still unknown. National and international public health authorities recommend caution and several prevention measures. Declaration of Zika virus infection is now mandatory in France. Given the available knowledge on Zika virus, we suggest here a review of the current recommendations for management of pregnancy in case of suspicious or infection by Zika virus in a pregnant woman.